To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care ...

Investigators designed and externally validated a prostate cancer death prediction model for risk stratification of men at the point of PSA screening.

Prostate cancer patients with metastatic disease and low-volume primary tumors appear to have a poor prognosis, according to ...

In this cohort study, a novel prognostic model was developed to estimate prostate cancer-specific mortality (PCSM) while ...

Alpenglow Biosciences announced a partnership with PathNet to help commercialize use of the startup's 3D microscope ...

To develop and validate an algorithm to extract clinically relevant data elements for prostate cancer (PCa) from prostate biopsy reports and magnetic resonance imaging (MRI) reports. MRI reports and ...

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today that the U.S. Food and Drug ...

The Gleason score reliably predicts lethal prostate cancer for up to 25 years after diagnosis. High-grade prostate cancers progress rapidly in the short term, while lower grade tumors can still lead ...

Lab service utilizes Envision Science's proprietary biomarkers and technology with a goal of improving diagnosis and grading of prostate cancer The new, tissue-based test service is intended to ...